POLN.SW Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Dzisiejszy wolumen	27 205.00
Średni wolumen	23 310.00
Kapitalizacja rynkowa	0.00
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-0.459
ATR14	CHF0 (0.00%)

Polyphor AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Polyphor AG Finanse

Annual	2020
Przychody:	CHF14.28M
Zysk brutto:	CHF0.00 (0.00 %)
EPS:	CHF-4.05

FY	2020
Przychody:	CHF14.28M
Zysk brutto:	CHF0.00 (0.00 %)
EPS:	CHF-4.05

FY	2019
Przychody:	CHF10 040.00
Zysk brutto:	CHF0.00 (0.00 %)
EPS:	CHF-5.85

FY	2018
Przychody:	CHF6.55M
Zysk brutto:	CHF6.55M (100.00 %)
EPS:	CHF-5.44

Financial Reports:

No articles found.

Polyphor AG

Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.